Prototypical Stressors

Showing 276 to 300 of 855 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

277	3,3'		None
278	3,3		None
279	Bioflavonoids		202: Inhibitor binding to topoisomerase II leading to infant leukaemia
280	Chlorpyrifos	Chlorpyrifos, CAS-RN: 2921-88-2, DTXSID4020458	3 AOPs 202: Inhibitor binding to topoisomerase II leading to infant leukaemia 490: Co-activation of IP3R and RyR leads to reduced IQ and increased socio-economic burden through non-cholinergic mechanisms 559: Inhibition of acetylcholinesterase (AChE) leading to arrhythmias
281	etoposide quinone		202: Inhibitor binding to topoisomerase II leading to infant leukaemia
282	Ketoconazole	Ketoconazole, CAS-RN: 65277-42-1, DTXSID7029879	4 AOPs 218: Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity 219: Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior 349: Inhibition of 11β-hydroxylase leading to decresed population trajectory 606: Ecdysone receptor antagonism leading to mortality via inhibition of chitin synthase 1
283	Stressor:159 dibenzofuran		None
284	Aristolochic acid	Aristolochic acid, CAS-RN: 313-67-7, DTXSID0040969	397: Bulky DNA adducts leading to mutations
285	Doxorubicin	Doxorubicin, CAS-RN: 23214-92-8, DTXSID8021480	None
286	Tebuconazole	Tebuconazole, CAS-RN: 107534-96-3, DTXSID9032113	None
287	Propiconazole	Propiconazole, CAS-RN: 60207-90-1, DTXSID8024280	None
288	Tioconazole	Tioconazole, CAS-RN: 65899-73-2, DTXSID3046619	None
289	Miconazole	Miconazole, CAS-RN: 22916-47-8, DTXSID6023319	None
290	Fluconazole	Fluconazole, CAS-RN: 86386-73-4, DTXSID3020627	None
291	Voriconazole	Voriconazole, CAS-RN: 137234-62-9, DTXSID5046485	None
292	Clotrimazole	Clotrimazole, CAS-RN: 23593-75-1, DTXSID7029871	None
293	Tacrorimus		None
294	Cyclosporin		2 AOPs 154: Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
295	serotonin transporter activation		3 AOPs 223: Serotonin transporter activation to seizure 224: Serotonin transporter activation to depression 225: Serotonin transporter activation to agitation
296	>85 known Cyp2E1 substrates		220: Cyp2E1 Activation Leading to Liver Cancer
297	NSAID (Nonsteroidal anti-inflammatory drug) inhibits PTGS1		227: NSAID induced PTGS1 inactivation to gastric ulcer
298	NSAID (Nonsteroidal anti-inflammatory drug) inhibits PTGS2		228: NSAID induced PTGS2 inactivation to gastric ulcer
299	Helicobacter pylori infection		229: Helicobacter pylori to gastric ulcer
300	PPARalpha antagonists		2 AOPs 6: Antagonist binding to PPARα leading to body-weight loss 529: Xenobiotic binding to peroxisome proliferator-activated receptors (PPARs) causes dysregulation of lipid metabolism leading to liver steatosis
301	NFE2/Nrf2 repression		232: NFE2/Nrf2 repression to steatosis